DETAILS, FICTION AND ABBV-744 IN ACUTE MYELOID LEUKEMIA (AML)

In Section C, individuals will acquire ABBV-744 and oral navitoclax. In Segment D, participants will acquire ABBV-744 and ruxolitinib. Participants will get treatment right until ailment progression or the individuals are not able to tolerate the study drugs.then market H3K27Ac at this area. Chromatin hyperacetylation could improve the accessibilit